CVRx Inc (NASDAQ:CVRX) Reports Q2 2025 Earnings: Revenue Slightly Beats Estimates While EPS Misses

CVRx Inc (NASDAQ:CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, reported its second-quarter 2025 financial results. The company posted revenue of $13.59 million, slightly surpassing analyst expectations of $13.49 million. However, its earnings per share (EPS) came in at -$0.57, missing the estimated -$0.53.

Key Financial Highlights vs. Estimates

• Revenue: Reported $13.59M vs. estimated $13.49M (a modest beat of ~0.7%).
• EPS: Reported -$0.57 vs. estimated -$0.53 (a wider loss than expected).
• Full-Year 2025 Estimates: Analysts project full-year sales of $57.21M, with an estimated EPS of -$2.05.
• Q3 2025 Outlook: Revenue is forecast at $14.83M, with an EPS estimate of -$0.50.

Market Reaction

Following the earnings release, CVRx shares saw a slight decline in after-hours trading, dropping approximately 0.4%. Over the past week, the stock has decreased by 9.4%, though it remains up nearly 14.9% over the past month. The muted after-hours reaction suggests investors were largely anticipating the mixed results, with the revenue beat offset by the deeper-than-expected loss.

Press Release Summary

The company highlighted its continued progress in commercializing Barostim, its neuromodulation therapy for heart failure patients. While no specific forward guidance was provided in the press release, the financials indicate steady revenue growth, albeit with persistent losses as the company invests in commercialization and R&D.

For a deeper dive into CVRx’s earnings history and future estimates, visit the earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.